Urgent action must be taken to address the dramatic rise of cancer drug prices and to better align prices with value, the President’s Cancer Panel urged in a recent report.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
